Role of oxidative stress in erythropoietin-induced hypertension in uremic rats

American Journal of Hypertension

Volumn 23, Issue 3, 2010, Pages 314-320

  Rancourt, Marie Eve ^a,b   Rodrigue, Marie Eve ^a,b   Agharazii, Mohsen ^a,b   Larivière, Richard ^a,b   Lebel, Marcel ^a,b  

^a Université Laval   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Blood pressure; Chronic renal failure; Endothelin 1; Erythropoietin; Hypertension; Oxidative stress; Tempol

Indexed keywords

CREATININE; ENDOTHELIN 1; ERYTHROPOIETIN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; TEMPOL;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL PARAMETERS; CONTROLLED STUDY; CREATININE CLEARANCE; GLOMERULOSCLEROSIS; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY FAILURE; KIDNEY FIBROSIS; MALE; NEPHRECTOMY; NEPHRITIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE; UREMIA; URINE VOLUME;

ANEMIA; ANIMALS; BLOOD PRESSURE; ENDOTHELIN-1; ERYTHROPOIETIN, RECOMBINANT; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; OXIDATIVE STRESS; RATS; RATS, WISTAR; UREMIA;

EID: 76749108501     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2009.242     Document Type: Article

References (32)

1. Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW. Hypertension following erythropoietin therapy in anemic hemodialysis patients. Am J Hypertens 1990; 3:947-955.
2. Lebel M, Kingma I, Grose JH, Langlois S. Hemodynamic and hormonal changes during erythropoietin therapy in hemodialysis patients. J Am Soc Nephrol 1998; 9:97-104.
3. Ludwig H, Fritz E, Kotzmann H, Höcker P, Gisslinger H, Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990; 322:1693-1699. (Pubitemid 20231526)
4. Berglund B, Ekblom B. Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy men. J Intern Med 1991; 229:125-130.
5. Vaziri ND, Zhou XJ, Naqvi F, Smith J, Oveisi F, Wang ZQ, Purdy RE. Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure. Am J Physiol 1996; 271:E113-E122.
6. Lacasse-M S, Kingma I, Larivière R, Grose JH, Lebel M. Uremia enhances the blood pressure response to erythropoietin. Clin Exp Hypertens 1997; 19: 389-401.
7. Rodrigue ME, Brochu I, D' orléans-Juste P, Larivièrea R, Lebel M. Effect of erythropoietin on blood pressure and on the vascular endothelial ET-1/ETB receptor system. Am J Hypertens 2008; 21:639-643.
8. Eggena P, Willsey P, Jamgotchian N, Truckenbrod L, Hu MS, Barrett JD, Eggena M P, Clegg K, Nakhoul F, Lee DB. Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems. Am J Physiol 1991; 261:E642-E646.
9. Lebel M, Rodrigue ME, Agharazii M, Larivière R. Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin. Am J Hypertens 2006; 19:1286-1292.
10. Rodrigue ME, Moreau C, Larivière R, Lebel M. Relationship between eicosanoids and endothelin-1 in the pathogenesis of erythropoietin-induced hypertension in uremic rats. J Cardiovasc Pharmacol 2003; 41:388-395.
11. Larivière R, Lebel M, Kingma I, Grose JH, Boucher D. Effects of losartan and captopril on endothelin-1 production in blood vessels and glomeruli of rats with reduced renal mass. Am J Hypertens 1998; 11:989-997.
12. Orisio S, Benigni A, Bruzzi I, Corna D, Perico N, Zoja C, Benatti L, Remuzzi G. Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int 1993; 43:354-358.
13. Lebel M, Lacasse-M S, Larivière R, Kingma I, Grose JH. Plasma and blood vessel endothelin-1 concentrations in hypertensive uremic rats treated with erythropoietin. Clin Exp Hypertens 1998; 20:939-951.
14. Brochu E, Lacasse S, Larivière R, Kingma I, Grose JH, Lebel M. Differential effects of endothelin-1 antagonists on erythropoietin-induced hypertension in renal failure. J Am Soc Nephrol 1999; 10:1440-1446.
15. Boulanger C, Lüscher TF. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest 1990; 85:587-590.
16. Morris ST, McMurray JJ, Spiers A, Jardine AG. Impaired endothelial function in isolated human uremic resistance arteries. Kidney Int 2001; 60:1077-1082.
17. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339:572-575.
18. Vaziri ND, Dicus M, Ho ND, Boroujerdi-Rad L, Sindhu RK. Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int 2003; 63:179-185.
19. Larivière R, D'Amours M, Lebel M, Kingma I, Grose JH, Caron L. Increased immunoreactive endothelin-1 levels in blood vessels and glomeruli of rats with reduced renal mass. Kidney Blood Press Res 1997; 20:372-380.
20. McIntyre M, Bohr D F, Dominiczak AF. Endothelial function in hypertension: the role of superoxide anion. Hypertension 1999; 34:539-545.
21. Ni Z, Wang XQ, Vaziri ND. Nitric oxide metabolism in erythropoietin- induced hypertension: effect of calcium channel blockade. Hypertension 1998; 32: 724-729.
22. Kaehler J, Sill B, Koester R, Mittmann C, Orzechowski HD, Muenzel T, Meinertz T. Endothelin-1 mRNA and protein in vascular wall cells is increased by reactive oxygen species. Clin Sci 2002; 103 Suppl 48:176S-178S.
23. Dumont Y, D'Amours M, Lebel M, Larivière R. Supplementation with a low dose of L-arginine reduces blood pressure and endothelin-1 production in hypertensive uraemic rats. Nephrol Dial Transplant 2001; 16:746-754.
24. Garcia DL, Anderson S, Rennke HG, Brenner BM. Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass. Proc Natl Acad Sci USA 1988; 85:6142-6146.
25. Torralbo A, Blanco J, Fontanellas A, Herrero JA, Cruceyra A, González-Lopez P, Barrientos A. Long-term erythropoietin in rats with reduced renal mass. Nephron 1996; 73:280-285.
26. Widstam-Attorps U, Berg U, Bohman SO, Lefvert AK. Proteinuria and renal function in relation to renal morphology. A clinicopathological study of IgA nephropathy at the time of kidney biopsy. Clin Nephrol 1992; 38:245-253.
27. Lavoie P, Robitaille G, Agharazii M, Ledbetter S, Lebel M, Larivière R. Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats. J Hypertens 2005; 23:1895-1903.
28. Laplante MA, Wu R, Moreau P, de Champlain J. Endothelin mediates superoxide production in angiotensin II-induced hypertension in rats. Free Radic Biol Med 2005; 38:589-596.
29. Galle J, Lehmann-Bodem C, Hübner U, Heinloth A, Wanner C. CyA and OxLDL cause endothelial dysfunction in isolated arteries through endothelin-mediated stimulation of O(2)(-) formation. Nephrol Dial Transplant 2000; 15:339-346.
30. Elmarakby AA, Dabbs Loomis E, Pollock JS, Pollock DM. ETA receptor blockade attenuates hypertension and decreases reactive oxygen species in ETB receptor-deficient rats. J Cardiovasc Pharmacol 2004; 44 Suppl 1: S7-10.
31. Wang HD, Xu S, Johns DG, Du Y, Quinn MT, Cayatte AJ, Cohen RA. Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ Res 2001; 88:947-953.
32. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000; 86:494-501.